Cost-effectiveness of statins

American Journal of Cardiology

Volumn 82, Issue 11, 1998, Pages 1357-1363

  Huse, Daniel M ^b   Russell, Mason W ^b   Miller, Jeffrey D ^b   Kraemer, Dale F ^b   D'Agostino, Ralph B ^b   Ellison, R Curtis ^b   Hartz, Stuart C ^a  

^a Medical Research International   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN;

ARTICLE; CORONARY ARTERY DISEASE; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; HEALTH CARE COST; LIFE EXPECTANCY; LIPID BLOOD LEVEL; PACKAGING; PRIORITY JOURNAL;

AGED; ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MALE; MARKOV CHAINS; MIDDLE AGED; PRAVASTATIN; PYRROLES; SIMVASTATIN;

EID: 18144444323     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00641-9     Document Type: Article

References (23)

1. 1. Glick H, Heyse JF, Thompson D, Epstein RS, Smith ME, Oster G. A model for evaluating the cost-effectiveness of cholesterol-lowering treatment. Int J Technol Assessment Health Care 1992;8:719-734.
2. 2. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost. Am J Public Health 1987;77:1417-1426.
3. 3. Thompson D, Oster G. Cost-effectiveness of drug therapy for hypercholesterolaemia: a review of the literature. PharmacoEcon 1992;2:34-42.
4. 4. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296:716-721.
5. 5. Russell MW, Huse DM, Drowns S, Hamel EC, Hartz SC. Direct medical costs of coronary artery disease in the United States. Am J Cardiol 1998;81:1110-1115.
6. 6. Goldman L, Garber AM, Grover SA, Hlatkey MA. Task force 6. Cost-effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996;27:1020-1030.
7. 7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 1993;269:3015-3023.
8. 8. Ezzati TM, Massey JT, Waksburg J, Chu A, Maurer KR. Sample design: Third National Health and Nutrition Examination Survey. Vital Health Stat 2 1992; 2(113):I-35.
9. 9. 1997 Physicians' Desk Reference. Montvale, NJ:Medical Economics Company, Inc., 1997.
10. 10. 1998 Physicians' Desk Reference. Montvale, NJ: Medical Economics, 1998.
11. 11. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
12. 12. National Center for Health Statistics. Vital Statistics of the United States, 1990. Volume II, Mortality, Part A. Rockville, MD: U.S. Public Health Service, 1994.
13. 13. Weinstein MC, Read JL, MacKay DN, Kresel JJ, Ashley H, Halvorsen KT, Hutchings HC. Cost-effectiveness choice of antimicrobial therapy for serious infections. J Gen Intern Med 1986;1:353-363.
14. 14. U.S. Government Printing Office. Federal Register, December 8, 1994. Washington, DC, 1994.
15. 15. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press, Inc., 1996:214-246.
16. 16. Andrade SE, Walker AM, Gottlieb EK, Hollenberg NK, Testa MA, Saperia GM, Platt R. Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings? New Engl J Med 1995;332: 1125-1131.
17. 17. Stinnett AA, Mittleman MA, Weinstein MC, Kuntz KM, Cohen DJ, Williams LW, Goldman PA, Staiger DO, Hunink MGM, Tsevat J, Tosteson ANA, Goldman E. The cost-effectiveness of dietary and pharmacologic therapy for cholesterol reduction in adults. In: Gold MR, Siegel JE, Russell EB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press, Inc., 1996:349-391.
18. 18. Siegel JE, Weinstein MC, Torrance GW. Reporting cost-effectiveness studies and results. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press, Inc., 1996:276-303.
19. 19. Bertolini S, Bon GB, Campbell LM, Farmer M, Langan J, Mahla G, Pauciullo P, Sirtori C, Egros F, Fayyad R, Nawrocki JW. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997;130:191-197.
20. 20. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-682.
21. 21. Leaverton PE, Sorlie PD, Kleinman JC, Dannenberg AL, Ingster-Moore L, Kannel WB, Cornoni-Huntley JC. Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. J Chron Dis 1987;40:775-784.
22. 22. Laurier D, Chau NP, Cazelles B, Segond P, and the PCV-METRA Group. Estimation of coronary heart disease risk in a French working population using a modified Framingham model. J Clin Epidemiol 1994;47:1353-1364.
23. 23. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti Atheroma Study (MAAS). Lancet. 1994;344:633-638.